(R)-Clevidipine-13C,d3

(R)-Clevidipine-13C,d3

• UNSPSC Description: (R)-Clevidipine-13C,d3 is the deuterium and 13C labeled Clevidipine[1]. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension[2].
• Target Antigen: Calcium Channel
• Type: Isotope-Labeled Compounds
• Related Pathways: Membrane Transporter/Ion Channel;Neuronal Signaling
• Applications: Neuroscience-Neuromodulation
• Field of Research: Cardiovascular Disease
• Solubility: 10 mM in DMSO
• Smiles: O=C(C1=C(C)NC(C)=C(C(OCOC(CCC)=O)=O)[C@@H]1C2=CC=CC(Cl)=C2Cl)O[13C]([2H])([2H])[2H]
• Molecular Weight: 460.33
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Yi X, Vivien B, Lynch C 3rd. Clevidipine blockade of L-type Ca2+ currents: steady-state and kinetic electrophysiological studies in guinea pigventricular myocytes.;Huraux C, Makita T, Szlam F, The vasodilator effects of clevidipine on human internal mammary artery. Anesth Analg. 1997 Nov;85(5):1000-4.;Ericsson H, et al. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999 Apr;8(1):29-37.;Ericsson H, et al. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. Drug Metab Dispos. 1999 May;27(5):558-64.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported